ArticleDrug design, development and therapy2019

Hyperprogression after anti-programmed cell death ligand-1 therapy in a patient with recurrent metastatic urothelial bladder carcinoma following first-line cisplatin-based chemotherapy: a case report.

Shiyu Mao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.